In conclusion, the emergence of MET amplification correlates with acquired resistance to anti-EGFR therapies in CRC, and possibly arises from an expansion of pre-existing MET amplified clones under the pressure of anti-EGFR therapy. This evidence concerns the gene MET and colorectal carcinoma.